October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2021-10-15T13:30:54-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

September 2021

July 2021

June 2021

The New Era in ADA Assays

2021-10-05T08:32:34-04:00June 7th, 2021|Webinars|

Anti-Drug Antibody (ADA) assays such as ligand-based assays are critical to assess the clinical efficacy and safety of a biological drug. ADA assays rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived (e.g., rabbits) pooled polyclonal antibodies (pAb) [...]

Polyclonal Antibody Sequencing with Only Proteomics

2021-10-05T08:27:24-04:00June 1st, 2021|Webinars|

Landing on the Moon with Mass Spectrometry: Polyclonal Sequencing with Only Proteomics Presented by Anthony Stajduhar, Director of International Business Development, Rapid Novor Over the past 5 years Rapid Novor has perfected monoclonal antibody sequencing, and is now sequencing mAbs from polyclonal mixtures using REpAb®.  After successfully launching their proteogenomics based [...]

September 2020

Leveraging Recombinant Patient Antibodies in Therapeutic Applications

2021-10-04T16:39:20-04:00September 3rd, 2020|Webinars|

Leveraging Recombinant Patient Antibodies in Therapeutic Applications Originally presented at PEGS Boston Virtual 2020 by Anthony Stajduhar, Director of International Business Development, Rapid Novor Our team has perfected the art of monoclonal antibody sequencing, and is now ready to demonstrate our ability to sequence mAbs from polyclonal mixtures. In this talk, Anthony [...]